|
1
|
Umeda T and Niijima T: Phase II study of
alpha interferon on renal cell carcinoma. Summary of three
collaborative trials. Cancer. 58:1231–1235. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Naito S, Yamamoto N, Takayama T, Muramoto
M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T,
Hoshi S, et al: Prognosis of Japanese metastatic renal cell
carcinoma patients in the cytokine era: a cooperative group report
of 1463 patients. Eur Urol. 57:317–325. 2010. View Article : Google Scholar
|
|
3
|
Kawashima H, Obayashi A, Kawamura M,
Masaki S, Tamada S, Iguchi T, Uchida J, Kuratsukuri K, Tanaka T and
Nakatani T: Galectin 9 and PINCH, novel immunotherapy targets of
renal cell carcinoma: a rationale to find potential tumor antigens
and the resulting cytotoxic T lymphocytes induced by the derived
peptides. BJU Int. 113:320–332. 2014. View Article : Google Scholar
|
|
4
|
Zhu C, Anderson AC, Schubart A, Xiong H,
Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3
ligand galectin-9 negatively regulates T helper type 1 immunity.
Nat Immunol. 6:1245–1252. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li Y, Dai C, Wu C and Liu Y: PINCH-1
promotes tubular epithelial-to-mesenchymal transition by
interacting with integrin-linked kinase. J Am Soc Nephrol.
18:2534–2543. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen K, Tu Y, Zhang Y, Blair HC, Zhang L
and Wu C: PINCH-1 regulates the ERK-Bim pathway and contributes to
apoptosis resistance in cancer cells. J Biol Chem. 283:2508–2517.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Van Poppel H, Joniau S and Van Gool SW:
Vaccine therapy in patients with renal cell carcinoma. Eur Urol.
55:1333–1342. 2009.PubMed/NCBI
|
|
8
|
Uemura H, Fujimoto K, Tanaka M, Yoshikawa
M, Hirao Y, Uejima S, Yoshikawa K and Itoh K: A phase I trial of
vaccination of CA9-derived peptides for HLA-A24-positive patients
with cytokine-refractory metastatic renal cell carcinoma. Clin
Cancer Res. 12:1768–1775. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rahma OE, Ashtar E, Ibrahim R, Toubaji A,
Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G,
et al: A pilot clinical trial testing mutant von Hippel-Lindau
peptide as a novel immune therapy in metastatic renal cell
carcinoma. J Transl Med. 8:82010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iiyama T, Udaka K, Takeda S, Takeuchi T,
Adachi YC, Ohtsuki Y, Tsuboi A, Nakatsuka S, Elisseeva OA, Oji Y,
et al: WT1 (Wilms’ tumor 1) peptide immunotherapy for renal cell
carcinoma. Microbiol Immunol. 51:519–530. 2007.
|
|
11
|
Sato E, Torigoe T, Hirohashi Y, Kitamura
H, Tanaka T, Honma I, Asanuma H, Harada K, Takasu H, Masumori N, et
al: Identification of an immunogenic CTL epitope of HIFPH3 for
immunotherapy of renal cell carcinoma. Clin Cancer Res.
14:6916–6923. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Walter S, Weinschenk T, Stenzl A, Zdrojowy
R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY,
Mendrzyk R, et al: Multipeptide immune response to cancer vaccine
IMA901 after single-dose cyclophosphamide associates with longer
patient survival. Nat Med. 18:1254–1261. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee CS, Cragg M, Glennie M and Johnson P:
Novel antibodies targeting immune regulatory checkpoints for cancer
therapy. Br J Clin Pharmacol. 76:233–247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mullard A: New checkpoint inhibitors ride
the immunotherapy tsunami. Nat Rev Drug Discov. 12:489–492. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ngiow SF, von Scheidt B, Akiba H, Yagita
H, Teng MW and Smyth MJ: Anti-TIM3 antibody promotes T cell
IFN-γ-mediated antitumor immunity and suppresses established
tumors. Cancer Res. 71:3540–3551. 2011.PubMed/NCBI
|
